documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
299 rows where docket_id = "FDA-2007-D-0369" and posted_year = 2025 sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, comment_start_date, comment_end_date, open_for_comment, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2007-D-0369-2421 | FDA | None FDA-2007-D-0369 | PSG_208564 Draft Guidance on Estradiol | Other | Guidance | 2025-12-16T05:00:00Z | 2025 | 12 | 2025-12-16T05:00:00Z | 2025-12-16T20:30:49Z | 1 | 0 | 09000064b90dccd3 | ||
| FDA-2007-D-0369-2420 | FDA | None FDA-2007-D-0369 | PSG_020908 Draft Guidance on Estradiol | Other | Guidance | 2025-12-16T05:00:00Z | 2025 | 12 | 2025-12-16T05:00:00Z | 2025-12-16T20:27:46Z | 1 | 0 | 09000064b90dccd1 | ||
| FDA-2007-D-0369-2419 | FDA | None FDA-2007-D-0369 | Product-Specific Guidance on Estradiol; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2025-12-08T05:00:00Z | 2025 | 12 | 2025-12-08T05:00:00Z | 2025-12-09T00:20:26Z | 2025-22249 | 0 | 0 | 09000064b90b585d | |
| FDA-2007-D-0369-2338 | FDA | None FDA-2007-D-0369 | PSG_216540 - Draft Guidance on Acoramidis Hydrochloride | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:42:47Z | 1 | 0 | 09000064b90ae511 | |
| FDA-2007-D-0369-2409 | FDA | None FDA-2007-D-0369 | PSG_215272 - Draft Guidance on Tapinarof | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:12:18Z | 1 | 0 | 09000064b90aee6c | |
| FDA-2007-D-0369-2392 | FDA | None FDA-2007-D-0369 | PSG_215014 - Draft Guidance on Pegcetacoplan | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:10:17Z | 1 | 0 | 09000064b90aee4a | |
| FDA-2007-D-0369-2407 | FDA | None FDA-2007-D-0369 | PSG_219209 - Draft Guidance on Suzetrigine | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:12:08Z | 1 | 0 | 09000064b90aee68 | |
| FDA-2007-D-0369-2402 | FDA | None FDA-2007-D-0369 | PSG_218944 - Draft Guidance on Revumenib Citrate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:11:43Z | 1 | 0 | 09000064b90aee5e | |
| FDA-2007-D-0369-2388 | FDA | None FDA-2007-D-0369 | PSG_022000 - Draft Guidance on Mesalamine | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:09:56Z | 1 | 0 | 09000064b90aee42 | |
| FDA-2007-D-0369-2360 | FDA | None FDA-2007-D-0369 | PSG_020062 - Draft Guidance on Diltiazem Hydrochloride | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:48:31Z | 1 | 0 | 09000064b90aee05 | |
| FDA-2007-D-0369-2382 | FDA | None FDA-2007-D-0369 | PSG_211913 - Draft Guidance on Isotretinoin | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:56:51Z | 1 | 0 | 09000064b90aee34 | |
| FDA-2007-D-0369-2351 | FDA | None FDA-2007-D-0369 | PSG_022012 - Draft Guidance on Carvedilol Phosphate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:46:04Z | 1 | 0 | 09000064b90ae582 | |
| FDA-2007-D-0369-2366 | FDA | None FDA-2007-D-0369 | PSG_214697 - Draft Guidance on Epinephrine | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:50:08Z | 1 | 0 | 09000064b90aee11 | |
| FDA-2007-D-0369-2374 | FDA | None FDA-2007-D-0369 | PSG_218230 - Draft Guidance on Gepotidacin Mesylate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:55:39Z | 1 | 0 | 09000064b90aee21 | |
| FDA-2007-D-0369-2369 | FDA | None FDA-2007-D-0369 | PSG_210132 - Draft Guidance on Estradiol; Progesterone | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:51:18Z | 1 | 0 | 09000064b90aee17 | |
| FDA-2007-D-0369-2377 | FDA | None FDA-2007-D-0369 | PSG_219141 - Draft Guidance on Hydrochlorothiazide | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:56:10Z | 1 | 0 | 09000064b90aee27 | |
| FDA-2007-D-0369-2379 | FDA | None FDA-2007-D-0369 | PSG_214581 - Draft Guidance on Hydroxychloroquine Sulfate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:56:28Z | 1 | 0 | 09000064b90aee2b | |
| FDA-2007-D-0369-2344 | FDA | None FDA-2007-D-0369 | PSG_208772 - Draft Guidance on Brigatinib | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:44:15Z | 1 | 0 | 09000064b90ae576 | |
| FDA-2007-D-0369-2393 | FDA | None FDA-2007-D-0369 | PSG_214511 - Draft Guidance on Pegulicianine Acetate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:10:23Z | 1 | 0 | 09000064b90aee4c | |
| FDA-2007-D-0369-2411 | FDA | None FDA-2007-D-0369 | PSG_021318 - Draft Guidance on Teriparatide | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:12:28Z | 1 | 0 | 09000064b90aee70 | |
| FDA-2007-D-0369-2412 | FDA | None FDA-2007-D-0369 | PSG_208088 - Draft Guidance on Testosterone Undecanoate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:12:33Z | 1 | 0 | 09000064b90aee72 | |
| FDA-2007-D-0369-2401 | FDA | None FDA-2007-D-0369 | PSG_009829 - Draft Guidance on Pyridostigmine Bromide | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:11:35Z | 1 | 0 | 09000064b90aee5c | |
| FDA-2007-D-0369-2404 | FDA | None FDA-2007-D-0369 | PSG_218160 - Draft Guidance on Selpercatinib | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:11:53Z | 1 | 0 | 09000064b90aee62 | |
| FDA-2007-D-0369-2383 | FDA | None FDA-2007-D-0369 | PSG_208462 - Draft Guidance on Ixazomib Citrate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:56:59Z | 1 | 0 | 09000064b90aee38 | |
| FDA-2007-D-0369-2367 | FDA | None FDA-2007-D-0369 | PSG_021323-ODT - Draft Guidance on Escitalopram Oxalate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:50:24Z | 1 | 0 | 09000064b90aee13 | |
| FDA-2007-D-0369-2385 | FDA | None FDA-2007-D-0369 | PSG_219132 - Draft Guidance on Levacetylleucine | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:57:14Z | 1 | 0 | 09000064b90aee3c | |
| FDA-2007-D-0369-2368 | FDA | None FDA-2007-D-0369 | PSG_214846 - Draft Guidance on Estradiol; Norethindrone Acetate; Relugolix | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:50:41Z | 1 | 0 | 09000064b90aee15 | |
| FDA-2007-D-0369-2353 | FDA | None FDA-2007-D-0369 | PSG_212839 - Draft Guidance on Cenobamate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:46:32Z | 1 | 0 | 09000064b90ae586 | |
| FDA-2007-D-0369-2343 | FDA | None FDA-2007-D-0369 | PSG_215064 - Draft Guidance on Birch Triterpenes | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2026-02-07T13:12:43Z | 1 | 0 | 09000064b90ae574 | |
| FDA-2007-D-0369-2375 | FDA | None FDA-2007-D-0369 | PSG_212097 - Draft Guidance on Glucagon | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:55:54Z | 1 | 0 | 09000064b90aee23 | |
| FDA-2007-D-0369-2362 | FDA | None FDA-2007-D-0369 | PSG_218860 - Draft Guidance on Elafibranor | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:49:00Z | 1 | 0 | 09000064b90aee09 | |
| FDA-2007-D-0369-2365 | FDA | None FDA-2007-D-0369 | PSG_019430 - Draft Guidance on Epinephrine | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:49:53Z | 1 | 0 | 09000064b90aee0f | |
| FDA-2007-D-0369-2381 | FDA | None FDA-2007-D-0369 | PSG_216017 - Draft Guidance on Iomeprol | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:56:43Z | 1 | 0 | 09000064b90aee2f | |
| FDA-2007-D-0369-2370 | FDA | None FDA-2007-D-0369 | PSG_018922-Tab - Draft Guidance on Etodolac | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:54:41Z | 1 | 0 | 09000064b90aee19 | |
| FDA-2007-D-0369-2364 | FDA | None FDA-2007-D-0369 | PSG_218171 - Draft Guidance on Ensartinib Hydrochloride | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:49:32Z | 1 | 0 | 09000064b90aee0d | |
| FDA-2007-D-0369-2356 | FDA | None FDA-2007-D-0369 | PSG_202806 - Draft Guidance on Dabrafenib Mesylate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:47:14Z | 1 | 0 | 09000064b90ae58c | |
| FDA-2007-D-0369-2339 | FDA | None FDA-2007-D-0369 | PSG_214056 - Draft Guidance on Apomorphine Hydrochloride | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:43:17Z | 1 | 0 | 09000064b90ae56c | |
| FDA-2007-D-0369-2398 | FDA | None FDA-2007-D-0369 | PSG_009170-ODT - Draft Guidance on Primidone | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:11:00Z | 1 | 0 | 09000064b90aee56 | |
| FDA-2007-D-0369-2399 | FDA | None FDA-2007-D-0369 | PSG_015193 - Draft Guidance on Pyridostigmine Bromide | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:11:06Z | 1 | 0 | 09000064b90aee58 | |
| FDA-2007-D-0369-2414 | FDA | None FDA-2007-D-0369 | PSG_214759 - Draft Guidance on Treosulfan | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:12:43Z | 1 | 0 | 09000064b90aee76 | |
| FDA-2007-D-0369-2397 | FDA | None FDA-2007-D-0369 | PSG_017469 - Draft Guidance on Prednisolone Acetate | Other | Letter(s) | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:10:44Z | 1 | 0 | 09000064b90aee54 | |
| FDA-2007-D-0369-2390 | FDA | None FDA-2007-D-0369 | PSG_021636 - Draft Guidance on Omeprazole; Sodium Bicarbonate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:10:07Z | 1 | 0 | 09000064b90aee46 | |
| FDA-2007-D-0369-2417 | FDA | None FDA-2007-D-0369 | PSG_022103 - Draft Guidance on Trospium Chloride | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:13:00Z | 1 | 0 | 09000064b90aee7c | |
| FDA-2007-D-0369-2405 | FDA | None FDA-2007-D-0369 | PSG_215256 - Draft Guidance on Semaglutide | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:11:58Z | 1 | 0 | 09000064b90aee64 | |
| FDA-2007-D-0369-2406 | FDA | None FDA-2007-D-0369 | PSG_021938 - Draft Guidance on Sunitinib Malate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:12:03Z | 1 | 0 | 09000064b90aee66 | |
| FDA-2007-D-0369-2408 | FDA | None FDA-2007-D-0369 | PSG_217439 - Draft Guidance on Talazoparib Tosylate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:12:13Z | 1 | 0 | 09000064b90aee6a | |
| FDA-2007-D-0369-2413 | FDA | None FDA-2007-D-0369 | PSG_215866 - Draft Guidance on Tirzepatide | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:12:38Z | 1 | 0 | 09000064b90aee74 | |
| FDA-2007-D-0369-2391 | FDA | None FDA-2007-D-0369 | PSG_217171 - Draft Guidance on Pegcetacoplan | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:10:12Z | 1 | 0 | 09000064b90aee48 | |
| FDA-2007-D-0369-2400 | FDA | None FDA-2007-D-0369 | PSG_217604 - Draft Guidance on Pyridostigmine Bromide | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:11:19Z | 1 | 0 | 09000064b90aee5a | |
| FDA-2007-D-0369-2389 | FDA | None FDA-2007-D-0369 | PSG_213593 - Draft Guidance on Omeprazole; Sodium Bicarbonate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:10:02Z | 1 | 0 | 09000064b90aee44 | |
| FDA-2007-D-0369-2387 | FDA | None FDA-2007-D-0369 | PSG_206321 - Draft Guidance on Liraglutide | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:09:51Z | 1 | 0 | 09000064b90aee40 | |
| FDA-2007-D-0369-2350 | FDA | None FDA-2007-D-0369 | PSG_022556 - Draft Guidance on Carbinoxamine Maleate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:45:51Z | 1 | 0 | 09000064b90ae580 | |
| FDA-2007-D-0369-2371 | FDA | None FDA-2007-D-0369 | PSG_212102 - Draft Guidance on Fenfluramine Hydrochloride | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:54:52Z | 1 | 0 | 09000064b90aee1b | |
| FDA-2007-D-0369-2361 | FDA | None FDA-2007-D-0369 | PSG_218711 - Draft Guidance on Docetaxel | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:48:45Z | 1 | 0 | 09000064b90aee07 | |
| FDA-2007-D-0369-2376 | FDA | None FDA-2007-D-0369 | PSG_210134 - Draft Guidance on Glucagon | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:56:03Z | 1 | 0 | 09000064b90aee25 | |
| FDA-2007-D-0369-2357 | FDA | None FDA-2007-D-0369 | PSG_214231 - Draft Guidance on Dasiglucagon Hydrochloride | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:47:34Z | 1 | 0 | 09000064b90ae58e | |
| FDA-2007-D-0369-2340 | FDA | None FDA-2007-D-0369 | PSG_214927 - Draft Guidance on Arimoclomol Citrate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:43:26Z | 1 | 0 | 09000064b90ae56e | |
| FDA-2007-D-0369-2345 | FDA | None FDA-2007-D-0369 | PSG_215935 - Draft Guidance on Budesonide | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:44:28Z | 1 | 0 | 09000064b90ae578 | |
| FDA-2007-D-0369-2418 | FDA | None FDA-2007-D-0369 | PSG_214938 - Draft Guidance on Vosoritide | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-08T10:00:23Z | 1 | 0 | 09000064b90aee7e | |
| FDA-2007-D-0369-2359 | FDA | None FDA-2007-D-0369 | PSG_218730 - Draft Guidance on Deutivacaftor; Tezacaftor; Vanzacaftor Calcium | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:48:17Z | 1 | 0 | 09000064b90aee03 | |
| FDA-2007-D-0369-2373 | FDA | None FDA-2007-D-0369 | PSG_020121 - Draft Guidance on Fluticasone Propionate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:55:30Z | 1 | 0 | 09000064b90aee1f | |
| FDA-2007-D-0369-2358 | FDA | None FDA-2007-D-0369 | PSG_017922 - Draft Guidance on Desmopressin Acetate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:47:49Z | 1 | 0 | 09000064b90ae590 | |
| FDA-2007-D-0369-2384 | FDA | None FDA-2007-D-0369 | PSG_205388 - Draft Guidance on Ketorolac Tromethamine; Phenylephrine Hydrochloride | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:57:07Z | 1 | 0 | 09000064b90aee3a | |
| FDA-2007-D-0369-2352 | FDA | None FDA-2007-D-0369 | PSG_216165 - Draft Guidance on Cefepime Hydrochloride; Enmetazobactam | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:46:18Z | 1 | 0 | 09000064b90ae584 | |
| FDA-2007-D-0369-2380 | FDA | None FDA-2007-D-0369 | PSG_216016 - Draft Guidance on Iomeprol | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:56:36Z | 1 | 0 | 09000064b90aee2d | |
| FDA-2007-D-0369-2363 | FDA | None FDA-2007-D-0369 | PSG_217660 - Draft Guidance on Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:49:16Z | 1 | 0 | 09000064b90aee0b | |
| FDA-2007-D-0369-2372 | FDA | None FDA-2007-D-0369 | PSG_215168 - Draft Guidance on Flurpiridaz F-18 | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:55:21Z | 1 | 0 | 09000064b90aee1d | |
| FDA-2007-D-0369-2342 | FDA | None FDA-2007-D-0369 | PSG_207924 - Draft Guidance on Baricitinib | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:43:47Z | 1 | 0 | 09000064b90ae572 | |
| FDA-2007-D-0369-2347 | FDA | None FDA-2007-D-0369 | PSG_215430 - Draft Guidance on Bupropion Hydrochloride; Dextromethorphan Hydrobromide | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:44:56Z | 1 | 0 | 09000064b90ae57c | |
| FDA-2007-D-0369-2341 | FDA | None FDA-2007-D-0369 | PSG_017851 - Draft Guidance on Baclofen | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:43:37Z | 1 | 0 | 09000064b90ae570 | |
| FDA-2007-D-0369-2410 | FDA | None FDA-2007-D-0369 | PSG_213931 - Draft Guidance on Tenapanor Hydrochloride | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:12:23Z | 1 | 0 | 09000064b90aee6e | |
| FDA-2007-D-0369-2395 | FDA | None FDA-2007-D-0369 | PSG_214770 - Draft Guidance on Poscaconazole | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:10:33Z | 1 | 0 | 09000064b90aee50 | |
| FDA-2007-D-0369-2403 | FDA | None FDA-2007-D-0369 | PSG_217242 - Draft Guidance on Roflumilast | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-23T10:00:12Z | 1 | 0 | 09000064b90aee60 | |
| FDA-2007-D-0369-2415 | FDA | None FDA-2007-D-0369 | PSG_214324 - Draft Guidance on Treprostinil | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:12:48Z | 1 | 0 | 09000064b90aee78 | |
| FDA-2007-D-0369-2386 | FDA | None FDA-2007-D-0369 | PSG_022341 - Draft Guidance on Liraglutide | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:09:46Z | 1 | 0 | 09000064b90aee3e | |
| FDA-2007-D-0369-2396 | FDA | None FDA-2007-D-0369 | PSG_019561 - Draft Guidance on Potassium chloride | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:10:38Z | 1 | 0 | 09000064b90aee52 | |
| FDA-2007-D-0369-2416 | FDA | None FDA-2007-D-0369 | PSG_017340 - Draft Guidance on Tretinoin | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:12:53Z | 1 | 0 | 09000064b90aee7a | |
| FDA-2007-D-0369-2394 | FDA | None FDA-2007-D-0369 | PSG_216483 - Draft Guidance on Pivmecillinam Hydrochloride | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T23:10:28Z | 1 | 0 | 09000064b90aee4e | |
| FDA-2007-D-0369-2349 | FDA | None FDA-2007-D-0369 | PSG_017769 - Draft Guidance on Calcitonin Salmon | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:45:35Z | 1 | 0 | 09000064b90af592 | |
| FDA-2007-D-0369-2378 | FDA | None FDA-2007-D-0369 | PSG_018303 - Draft Guidance on Hydrochlorothiazide; Metoprolol Tartrate | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:56:19Z | 1 | 0 | 09000064b90aee29 | |
| FDA-2007-D-0369-2354 | FDA | None FDA-2007-D-0369 | PSG_218808 - Draft Guidance on Crinecerfont | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:46:46Z | 1 | 0 | 09000064b90ae588 | |
| FDA-2007-D-0369-2348 | FDA | None FDA-2007-D-0369 | PSG_020664 - Draft Guidance on Cabergoline | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:45:11Z | 1 | 0 | 09000064b90ae57e | |
| FDA-2007-D-0369-2355 | FDA | None FDA-2007-D-0369 | PSG_218820 - Draft Guidance on Crinecerfont | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:46:59Z | 1 | 0 | 09000064b90ae58a | |
| FDA-2007-D-0369-2346 | FDA | None FDA-2007-D-0369 | PSG_020929 - Draft Guidance on Budesonide | Other | Guidance | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T05:00:00Z | 2026-02-04T04:59:59Z | 2025-12-05T20:44:46Z | 1 | 0 | 09000064b90ae57a | |
| FDA-2007-D-0369-2337 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2025-12-05T05:00:00Z | 2025 | 12 | 2025-12-05T19:22:56Z | 2025-22131 | 0 | 0 | 09000064b90b00b7 | ||
| FDA-2007-D-0369-2297 | FDA | None FDA-2007-D-0369 | PSG_022383 - Draft Guidance on Indacaterol Maleate | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:09:40Z | 1 | 0 | 09000064b908bac8 | |
| FDA-2007-D-0369-2272 | FDA | None FDA-2007-D-0369 | PSG_021658 - Draft Guidance on Ciclesonide | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:07:23Z | 1 | 0 | 09000064b908c9be | |
| FDA-2007-D-0369-2281 | FDA | None FDA-2007-D-0369 | PSG_207534 - Draft Guidance on Epinephrine | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:08:11Z | 1 | 0 | 09000064b908baa8 | |
| FDA-2007-D-0369-2325 | FDA | None FDA-2007-D-0369 | PSG_218010 - Draft Guidance on Travoprost | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:12:07Z | 1 | 0 | 09000064b908ca20 | |
| FDA-2007-D-0369-2264 | FDA | None FDA-2007-D-0369 | PSG_217424 - Draft Guidance on Berdazimer Sodium | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:06:35Z | 1 | 0 | 09000064b908c9ae | |
| FDA-2007-D-0369-2329 | FDA | None FDA-2007-D-0369 | PSG_209241 - Draft Guidance on Valbenazine Tosylate | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:12:31Z | 1 | 0 | 09000064b908ca28 | |
| FDA-2007-D-0369-2285 | FDA | None FDA-2007-D-0369 | PSG_210589 - Draft Guidance on Fish Oil Triglycerides | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:08:35Z | 1 | 0 | 09000064b908bab0 | |
| FDA-2007-D-0369-2301 | FDA | None FDA-2007-D-0369 | PSG_204410 - Draft Guidance on Draft Guidance on Macitentan | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:10:01Z | 1 | 0 | 09000064b908bad0 | |
| FDA-2007-D-0369-2276 | FDA | None FDA-2007-D-0369 | PSG_216099 - Draft Guidance on Dasatinib | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:07:45Z | 1 | 0 | 09000064b908ba9e | |
| FDA-2007-D-0369-2290 | FDA | None FDA-2007-D-0369 | PSG_210828 - Draft Guidance on Gallium GA 68 Edotreotide | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:09:02Z | 1 | 0 | 09000064b908baba | |
| FDA-2007-D-0369-2310 | FDA | None FDA-2007-D-0369 | PSG_208051 - Draft Guidance on Neratinib Maleate | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:10:48Z | 1 | 0 | 09000064b908ca02 | |
| FDA-2007-D-0369-2326 | FDA | None FDA-2007-D-0369 | PSG_216158 - Draft Guidance on Trospium Chloride; Xanomeline Tartrate | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:12:13Z | 1 | 0 | 09000064b908ca22 | |
| FDA-2007-D-0369-2312 | FDA | None FDA-2007-D-0369 | PSG_204508 - Draft Guidance on Olive Oil; Soybean Oil | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:10:58Z | 1 | 0 | 09000064b908ca06 | |
| FDA-2007-D-0369-2273 | FDA | None FDA-2007-D-0369 | PSG_213227 - Draft Guidance on Copper CU-64 Dotatate | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:07:28Z | 1 | 0 | 09000064b908c9c0 | |
| FDA-2007-D-0369-2304 | FDA | None FDA-2007-D-0369 | PSG_216755 - Draft Guidance on Metronidazole | Other | Guidance | 2025-11-21T05:00:00Z | 2025 | 11 | 2025-11-21T05:00:00Z | 2026-01-21T04:59:59Z | 2025-11-21T20:10:18Z | 1 | 0 | 09000064b908c9d8 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;